CDNA CAREDX INC

CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings

CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings

CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.

As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host “Next Generation Care for Kidney Transplant Patients,” a 30-minute exhibitor showcase on April 6th from 11:00-11:30 a.m. Eastern Time.



Program details:

  • Innovations in Kidney Transplant Care, with Dr. Christopher Boshkos, Medical Director of Kidney Transplantation at CareDx



  • AlloSure: Standard of Care for Kidney Transplant Surveillance, with Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine

“I’m looking forward to highlighting research from the RADAR study, where AlloSure differentiates ambiguous allograft rejection in borderline cases, and presenting select case studies to illustrate long-term patient follow up with AlloSure from the KOAR registry,” said Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine.

In addition, CareDx is sponsoring the “Diagnosis of Acute Rejection in Kidney Transplantation: A Clinical Update,” a continuing medical education (CME) program on April 8th from 12:30–1:30 p.m. Eastern Time.

Program details:

  • Acute Rejection in Kidney Transplantation: Pathophysiology and Impact on Outcomes, presented by Tarek Alhamad, MD, MS, Medical Director of Transplant Nephrology at Washington University School of Medicine in St. Louis

  • Diagnostic Modalities for Acute Rejection in Kidney, presented by Deirdre Sawinski, MD, Assistant Medical Director, Penn Kidney Pancreas Transplant Program

  • Advances in Non-Invasive Diagnosis of Acute Rejection in Kidney Transplantation, presented by Jonathan Bromberg, MD, PhD, Vice Chair for Research, University of Maryland School of Medicine

“The NKF Spring Clinical Meetings are always a highlight for us,” said Dr. Sham Dholakia, SVP Medical Affairs, CareDx. “We are excited to showcase the latest in kidney transplant surveillance data at this great event.”

Additional information is available at

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: .

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

Investor Relations

Greg Chodaczek

347-610-7010



EN
05/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...

 PRESS RELEASE

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung...

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gim...

 PRESS RELEASE

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 o...

In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents tha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch